Patients undergoing haemodialysis are predisposed to serum lipid abnormalities that can accelerate the development of atherosclerosis. Serum lipid levels must therefore be controlled over a long period. For patients with reduced renal function (including dialysis patients), special attention must be paid to hyperlipidaemia therapy, particularly drug selection. In this study, 30 mg/day fluvastatin was administered orally to five patients receiving maintenance haemodialysis. Their serum lipid levels and blood biochemistry were monitored during the 6 months of fluvastatin administration, and the pharmacokinetic parameters calculated. The therapeutic efficacy and safety of fluvastatin were demonstrated in this patient group. Furthermore, fluvastatin is not influenced by the dialysis membrane and does not accumulate in haemodialysis patients with hyperlipidaemia.
Introduction
The number of patients requiring long-term haemodialysis (HD) is increasing with technical improvements in dialysis. The prognosis of such patients correlates with renal failure complications: in particular, the cardiovascular complications caused by atherosclerosis. Many chronic HD patients have cardiovascular complications, 1, 2 and hyperlipidaemia and hypertension are important risk factors. 3 -7 Currently, 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors are widely used to treat hyperlipidaemia, but there are few reports on the use of HMG-CoA reductase inhibitors in hyperlipidaemia patients undergoing HD. 8 -10 This study investigates the effect of fluvastatin, a totally synthetic HMG-CoA reductase inhibitor, 11 on serum lipid levels, as well as the effect of HD on fluvastatin plasma concentrations.
Patients and methods PATIENTS
Patients with chronic renal failure were enrolled in this study. All patients had serum total cholesterol levels (TC) of > 220 mg/dl, even after initial diet therapy, and their hypercholesterolaemia required drug therapy. Patients with a clinical history of hypersensitivity to an HMG-CoA reductase inhibitor or those with serious hepatic function impairment were excluded. Apart from the study drug, no other antihyperlipidaemia drugs were used during the study period.
All patients gave informed consent before drug administration but ethics committee approval was not required.
DRUG ADMINISTRATION
A dose of 30 mg fluvastatin was taken orally, after dinner, every day for 6 months followed by immediate initiation of HD.
DIALYSIS
The following dialysis membranes were used: PS-1.6UW (polysulfone thin film; Kawasumi Laboratories Inc., Tokyo, Japan), FB-190P (thin film containing triacetate salt; Nipro Corporation, Osaka, Japan), and CL-EE-15N (Exebrane thin film; Asahi Medical Co. Ltd, Tokyo, Japan). The conditions for dialysis were: flow rate of dialysed blood, 500 ml/min; flow rate of blood, 180 -300 ml/min; and the duration of dialysis, 3 -4 h.
SERUM LIPIDS AND LABORATORY TESTS
Levels of total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transferase (γ-GTP), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), serum creatinine, uric acid and creatine kinase (CK) were measured at enrolment and 1 month, 2 months, 3 months and 6 months after starting fluvastatin therapy. Blood samples were withdrawn before dialysis, in a fasting state. TC and TG were measured by their respective enzyme assay, HDL-C by a precipitation method and LDL-C by a direct method. All other biochemical parameters were measured using standard laboratory tests (Osaka Kessei Co. Ltd, Osaka, Japan).
MEASUREMENT OF FLUVASTATIN CONCENTRATION
The fluvastatin concentration was measured 6 months after the start of therapy. Fluvastatin (30 mg) was administered orally. Venous blood samples (4 ml each) were withdrawn every hour from immediately before fluvastatin administration to 1 h after the end of HD. During HD, blood samples were taken from the channels either side of the dialysis membrane (inflow and outflow). Each sample was taken in a heparinized test tube. Plasma was separated by centrifugation, frozen and stored in the dark until the concentration of fluvastatin was measured by a modified high-performance liquid chromatography method. 12 Briefly, fluvastatin sodium and the internal standard were extracted from buffered plasma into methyl tert-butyl ether, followed by evaporation of an aliquot of the organic phase. After reconstituting the dried sample in a small volume of the mobile phase (methanol tetrabutylammonium fluoride), the sample was chromatographed on an output delivery system (ODS) column at 50°C. Fluorescence detection (excitation at 305 nm and emission at 380 nm) was used to monitor both fluvastatin (free acid) and the internal standard.
CALCULATION OF THE PHARMACOKINETIC PARAMETERS
The maximum plasma concentration (C max ) of fluvastatin and time to maximum concentration (T max ) were calculated. The halflife of elimination (t 1/2 ) was calculated from the elimination rate constant (Kel), which was determined by linearly regressing the logarithm of the plasma concentration in the elimination phase against time. The area under the plasma concentration against time curve (AUC) from time 0 (time of administration) to infinity (AUC 0 -∞ ) was calculated as the sum of the area from time 0 to the last measurement time (t) (AUC 0 -t ). The area from t to infinity was estimated by extrapolation to time infinity using Kel. Clearance of fluvastatin by dialysis was calculated from the plasma samples taken from either side of the dialysis membrane, and then the haematocrit value and plasma fluvastatin concentration were measured.
DATA AND STATISTICAL ANALYSIS
Serum lipid levels and other measurements were compared with their respective baseline values using the paired t-test. The significance level was set at 5%, two-tailed. The results are presented as the mean ± SE. A P-value < 0.05 was considered statistically significant.
Results
Five patients were recruited to the study and their demographic characteristics are shown in Table 1 . At baseline, the mean levels of serum lipids were: TC, 234.6 ± 8.2 mg/dl (normal range: 130 -219 mg/dl); TG, 139.5 ± 44.4 mg/dl (normal range: 35 -149 mg/dl); HDL-C, 51.6 ± 7.3 mg/dl (normal range: male, 40 -74 mg/dl, female, 40 -83 mg/dl); and LDL-C, 168.0 ± 19.7 mg/dl (normal range: 70 -130 mg/dl).
SERUM LIPIDS
Changes in the serum levels of TC, TG, HDL-C and LDL-C before and after fluvastatin administration are shown in Fig. 1 .
PLASMA FLUVASTATIN CONCENTRATION
The plasma fluvastatin concentration reached a peak 2 h after its administration and had disappeared by the time of the final blood sampling (Figs 2 and 3 ). The concentrations of fluvastatin in the patients immediately before HD were below the limit of detection.
The pharmacokinetic parameters calculated from the plasma fluvastatin concentrations are shown in Table 2. 47 N Ichimaru, S Takahara, T Moriyama et al. The fluvastatin concentrations in the plasma samples taken from the channels on either side of the dialysis membrane are shown in Fig. 3 . There was no significant difference in fluvastatin concentration in these two plasma samples.
Fluvastatin in haemodialysis patients

SIDE-EFFECTS AND LABORATORY TEST RESULTS
No side-effects attributable to fluvastatin administration were observed. Changes in the biochemical parameters measured are shown in Table 3 . There were no significant differences between any of the mean values before and after fluvastatin administration.
No abnormalities were observed in the blood biochemical tests in association with fluvastatin administration.
Discussion
Approximately 50% of (chronic) HD patients die from cardiovascular complications, especially heart failure, cerebrovascular diseases and myocardial infarction. These diseases are considered as sequelae of atherosclerosis. 1, 2 Abnormalities in lipid metabolism (an increase in TG, decrease in HDL-C and increase in TC 6,7 ) are observed in HD patients, suggesting a correlation with atherosclerosis. 3 -5 Lowering TC levels is Data are presented as mean ± SE. Fluvastatin in haemodialysis patients thought to be very important for preventing the development and progression of atherosclerosis in both HD and non-HD persons. The effects of HMG-CoA reductase inhibitors on serum lipid levels have been reported in many studies, but in comparison, the serum concentrations of HMG-CoA reductase inhibitors during HD have been only partially investigated. 8 -10 In our study, we demonstrated the safety of fluvastatin (30 mg/day orally for 6 months) in five HD patients with hypercholesterolaemia, and achieved a significant improvement in some serum lipid levels. We also measured plasma fluvastatin concentrations to analyse chronological changes in fluvastatin blood levels, and the effect of HD on fluvastatin plasma levels.
Serum levels of TC and LDL-C decreased significantly following fluvastatin admin-istration, and these decreases were maintained during the entire study period. These results are in accordance with those of a previous study where fluvastatin was administered to patients with decreased renal function. 13 No effects of fluvastatin on HDL-C and TG were detected in our study, and this is inconsistent with a previous report in which the HMG-CoA reductase inhibitor effectively lowered HDL-C and TG levels in HD patients. 8 -10 This difference is probably due to the fact that HDL-C and TG levels were both in the normal range in our patients before fluvastatin administration. Neither abnormalities in the clinical laboratory test values nor adverse reactions were observed in any of our patients.
Rhabdomyolysis has been reported as a serious and very rare side-effect of HMG-CoA reductase inhibitors, and was observed in some HD patients during treatment with pravastatin. 14 CK values were monitored periodically while our patients were treated with fluvastatin. None of them showed abnormal values or suspicious manifestations such as myalgia. The chronological changes in plasma fluvastatin concentrations during HD were no different to those in non-HD patients given the same drug dose. 15 Furthermore, the pharmacokinetic parameters (T max , C max , AUC and t 1/2 ) showed no difference between the HD and non-HD patients. The rate of removal of fluvastatin between inflow and outflow channels was nil, indicating that fluvastatin was not removed by HD. This result is explained by the fact that the protein binding rate of fluvastatin is 98% in plasma.
In our study the plasma fluvastatin concentration was not measured when dialysis was started, but after 6 months of daily therapy, the fluvastatin concentration before administering the daily dose was below the limit of detection. This result suggests a lack of drug accumulation in patients on maintenance HD. Previous studies measured the plasma concentrations of rovastatin 16 and pravastatin 17 after their administration to patients receiving HD, or to those with chronic renal failure. Gehr et al. 17 reported that the plasma pravastatin concentration after administration for 12 days was not significantly different from that after the initial administration, and that there was an increase in the AUC. Our plasma fluvastatin concentration results suggest that the pharmacokinetics in the HD patients are similar to those in the non-HD patients.
After oral intake, fluvastatin is absorbed from the intestine, metabolized in the liver and excreted from the kidneys to a small extent, 18 while the majority is excreted as bile. A drug that is not excreted from the kidneys in large quantities is preferable for HD patients whose renal functions are seriously impaired.
Fluvastatin is a useful drug for treating patients with hypercholesterolaemia who receive HD, since it is not affected by the dialysis membrane and does not accumulate in the body. Fluvastatin can be used to help prevent the development of atherosclerosis in HD patients, patients with slight to moderately decreased renal function, and in elderly people whose renal function is often reduced. 
